Please assess the completion status of the following clinical trial:

Trial Title: Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, hypopharynx, or larynx) or skin~* For patients with oropharyngeal cancer, p16 status is known or can be determined~* Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)~* Acceptable laboratory results as indicated by protocol~* Acceptable cardiac function as indicated by protocol~Exclusion Criteria:~* Received prior epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for recurrent or metastatic Squamous Cell Carcinoma (e.g., oral EGFR TKIs such as erlotinib, gefitinib, or afatinib)~* Family history of long corrected QT interval (QTc) syndrome~* Receiving medication that prolongs QT interval ,with a risk of causing Torsades de Pointes (TdP), unless ECG meets inclusion criteria while on a stable dose of the medication~* Family history of long QTc syndrome~* Symptomatic central nervous system (CNS) lesions, or CNS lesions that require therapy~* Radiation therapy within 2 weeks prior to the first dose of study medication~* Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication~* Concurrent active malignancy requiring systemic treatment~* Any other serious uncontrolled medical disorders or psychological conditions that may interfere with study conduct including but not limited to: clinically significant active infection~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TH-4000 (Tarloxotinib) (Type: EXPERIMENTAL): TH-4000 150 mg/m2 will be administered by IV infusion over 60 minutes on Days 1, 8, 15 and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).